Compare Stocks: VRAX, NVNO, ICCM, and INBS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ICCM IceCure Medical	$2.21 +3.3%	$2.93	$2.06 ▼ $42.00	$7.57M	0.45	168,528 shs	211,066 shs
INBS Intelligent Bio Solutions	$2.13 -2.7%	$2.20	$1.52 ▼ $24.90	$6.45M	4.25	333,033 shs	30,088 shs
NVNO enVVeno Medical	$10.49 -5.7%	$10.87	$8.67 ▼ $35.70	$7.29M	1.06	22,637 shs	54,139 shs
VRAX Virax Biolabs Group	$2.67 -6.3%	$3.12	$2.50 ▼ $21.75	$2.13M	1.37	973,320 shs	36,928 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ICCM IceCure Medical	0.00%	-0.90%	-26.33%	-7.53%	-92.63%
INBS Intelligent Bio Solutions	0.00%	-4.48%	-29.00%	-11.25%	-87.47%
NVNO enVVeno Medical	0.00%	-9.17%	-0.26%	+4.90%	-58.37%
VRAX Virax Biolabs Group	0.00%	+1.52%	-5.32%	-41.96%	-81.58%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ICCM IceCure Medical	$2.21 +3.3%	$2.93	$2.06 ▼ $42.00	$7.57M	0.45	168,528 shs	211,066 shs
INBS Intelligent Bio Solutions	$2.13 -2.7%	$2.20	$1.52 ▼ $24.90	$6.45M	4.25	333,033 shs	30,088 shs
NVNO enVVeno Medical	$10.49 -5.7%	$10.87	$8.67 ▼ $35.70	$7.29M	1.06	22,637 shs	54,139 shs
VRAX Virax Biolabs Group	$2.67 -6.3%	$3.12	$2.50 ▼ $21.75	$2.13M	1.37	973,320 shs	36,928 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ICCM IceCure Medical	0.00%	-0.90%	-26.33%	-7.53%	-92.63%
INBS Intelligent Bio Solutions	0.00%	-4.48%	-29.00%	-11.25%	-87.47%
NVNO enVVeno Medical	0.00%	-9.17%	-0.26%	+4.90%	-58.37%
VRAX Virax Biolabs Group	0.00%	+1.52%	-5.32%	-41.96%	-81.58%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ICCM IceCure Medical	2.20	Hold	$52.50	2,275.57% Upside
INBS Intelligent Bio Solutions	1.50	Reduce	N/A	N/A
NVNO enVVeno Medical	2.33	Hold	N/A	N/A
VRAX Virax Biolabs Group	2.00	Hold	$25.00	836.33% Upside

Current Analyst Ratings Breakdown

Latest VRAX, NVNO, ICCM, and INBS Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/14/2026	ICCM IceCure Medical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/17/2026	ICCM IceCure Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	INBS Intelligent Bio Solutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/7/2026	NVNO enVVeno Medical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/6/2026	VRAX Virax Biolabs Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/6/2026	NVNO enVVeno Medical	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/30/2026	NVNO enVVeno Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	INBS Intelligent Bio Solutions	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/15/2026	NVNO enVVeno Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ICCM IceCure Medical	$3.38M	2.24	N/A	N/A	$3.72 per share	0.59
INBS Intelligent Bio Solutions	$4.22M	1.53	N/A	N/A	$2.21 per share	0.96
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	$41.38 per share	N/A
VRAX Virax Biolabs Group	$10K	213.60	N/A	N/A	$42.23 per share	0.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ICCM IceCure Medical	-$15.06M	-$8.52	N/A	N/A	N/A	-427.67%	-174.26%	-112.58%	11/18/2026 (Estimated)
INBS Intelligent Bio Solutions	-$12.43M	-$9.02	N/A	N/A	N/A	-294.88%	-175.35%	-91.25%	11/11/2026 (Estimated)
NVNO enVVeno Medical	-$19.47M	-$19.33	N/A	N/A	N/A	N/A	-62.28%	-56.83%	10/30/2026 (Estimated)
VRAX Virax Biolabs Group	-$5.02M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	12/2/2026 (Estimated)

Latest VRAX, NVNO, ICCM, and INBS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2026	Q4 2026	INBS Intelligent Bio Solutions	-$1.58	-$0.90	+$0.68	-$0.90	$1.22 million	$1.15 million
7/30/2026	Q2 2026	NVNO enVVeno Medical	-$4.69	-$5.37	-$0.68	-$5.37	$1.00 million	N/A
7/3/2026	Q4 2026	VRAX Virax Biolabs Group	-$1.75	-$0.1950	+$1.5550	-$0.1950	$0.00 million	$0.01 million
6/30/2026	Q2 2026	ICCM IceCure Medical	N/A	-$1.60	N/A	-$1.5970	N/A	$0.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ICCM IceCure Medical	N/A	N/A	N/A	N/A	N/A
INBS Intelligent Bio Solutions	N/A	N/A	N/A	N/A	N/A
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ICCM IceCure Medical	N/A	2.88	2.44
INBS Intelligent Bio Solutions	N/A	1.44	1.35
NVNO enVVeno Medical	N/A	11.70	11.70
VRAX Virax Biolabs Group	N/A	9.97	9.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ICCM IceCure Medical	0.62%
INBS Intelligent Bio Solutions	32.97%
NVNO enVVeno Medical	34.71%
VRAX Virax Biolabs Group	8.61%

Insider Ownership

Company	Insider Ownership
ICCM IceCure Medical	2.44%
INBS Intelligent Bio Solutions	1.27%
NVNO enVVeno Medical	15.00%
VRAX Virax Biolabs Group	45.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ICCM IceCure Medical	60	3.43 million	3.34 million	Not Optionable
INBS Intelligent Bio Solutions	10	3.03 million	2.99 million	Not Optionable
NVNO enVVeno Medical	30	690,000	591,000	No Data
VRAX Virax Biolabs Group	5	800,000	438,000	Not Optionable

VRAX, NVNO, ICCM, and INBS Headlines

Recent News About These Companies

Virax Biolabs Expands ATM Share Offering With New SEC Filing

September 4, 2026 | tipranks.com

Virax Biolabs Shareholders Approve Major Capital Increase but Reject Governance Overhaul

August 26, 2026 | tipranks.com

Join Virax’s Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial Execution

August 20, 2026 | usatoday.com

Virax Biolabs Calls August 14 EGM to Approve Major Share Capital Increase

August 2, 2026 | theglobeandmail.com

RedChip Companies, Inc.: Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money Show on Bloomberg TV

July 20, 2026 | finanznachrichten.de

Virax Biolabs Boosts Liquidity, Secures Fosun Deal and Restores Nasdaq Compliance After Fiscal 2026 Report

July 17, 2026 | tipranks.com

Virax BioLabs Group Limited: Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

July 16, 2026 | finanznachrichten.de

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

July 16, 2026 | prnewswire.com

Virax Biolabs Raises $3.3 Million via Exercise of Investment Options and Issues New Warrants

July 10, 2026 | tipranks.com

Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

July 10, 2026 | prnewswire.com

Virax Biolabs Group Limited Ordinary Shares (VRAX) Institutional Holdings

July 10, 2026 | nasdaq.com

Virax Biolabs stock skyrockets 100% on exclusive distribution agreement

July 9, 2026 | msn.com

Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

July 9, 2026 | prnewswire.com

Virax Biolabs shares double after exclusive Fosun distribution agreement (VRAX)

July 9, 2026 | msn.com

Why this biotech stock more than tripled on Thursday

July 9, 2026 | invezz.comI

Virax Biolabs Jumps on Fosun Diagnostics Supply Agreement

July 9, 2026 | quiverquant.comQ

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

July 9, 2026 | prnewswire.com

Virax Biolabs Group announces 1-for-25 share consolidation

June 25, 2026 | msn.com

Virax Biolabs Approves 1-for-25 Share Consolidation to Maintain Nasdaq Listing

June 24, 2026 | tipranks.com

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation

June 24, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX, NVNO, ICCM, and INBS Company Descriptions

IceCure Medical NASDAQ:ICCM

$2.21 +0.07 (+3.27%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.17 -0.04 (-1.81%)

As of 09/11/2026 07:55 PM Eastern

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Intelligent Bio Solutions NASDAQ:INBS

$2.13 -0.06 (-2.74%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.15 +0.02 (+1.13%)

As of 09/11/2026 07:59 PM Eastern

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

enVVeno Medical NASDAQ:NVNO

$10.49 -0.63 (-5.67%)

Closing price 09/11/2026 03:56 PM Eastern

Extended Trading

$9.91 -0.58 (-5.54%)

As of 09/11/2026 05:52 PM Eastern

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Virax Biolabs Group NASDAQ:VRAX

$2.67 -0.18 (-6.32%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.74 +0.08 (+2.81%)

As of 09/11/2026 07:54 PM Eastern

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRAX, NVNO, ICCM, and INBS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRAX, NVNO, ICCM, and INBS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRAX, NVNO, ICCM, and INBS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX, NVNO, ICCM, and INBS Company Descriptions

IceCure Medical NASDAQ:ICCM

Intelligent Bio Solutions NASDAQ:INBS

enVVeno Medical NASDAQ:NVNO

Virax Biolabs Group NASDAQ:VRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRAX, NVNO, ICCM, and INBS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRAX, NVNO, ICCM, and INBS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRAX, NVNO, ICCM, and INBS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX, NVNO, ICCM, and INBS Company Descriptions

IceCure Medical NASDAQ:ICCM

Intelligent Bio Solutions NASDAQ:INBS

enVVeno Medical NASDAQ:NVNO

Virax Biolabs Group NASDAQ:VRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools